Skip to main content
Premium Trial:

Request an Annual Quote

Tecan, Kinovate Life Sciences, Biophage Pharma, Invitrogen

Premium
Tecan this week announced the launch of HydroFlex, an application platform for automated vacuum filtration, magnetic bead separation, and plate washing. According to the manufacturer, the product automates a range of 96-well format applications, including PCR clean-up and bead assays, ELISAs, cell assays, and protein arrays.
 
The HydroFlex offers a tunable vacuum range from -50 mbar to -850 mbar for both high- and low-vacuum applications.
 
The HydroFlex includes a shaking mode to enhance bead mixing, and magnets to settle the beads.
 
The platform’s online control features include a process control manifold that monitors all overflow wash steps, and a liquid level detection system to monitor filling levels in wash buffers and waste bottles.
 
The HydroFlex can be operated as a stand-alone instrument with its built-in keypad, or by using the HydroControl software for pre-programming of wash cycles and plate parameters. The software has been designed to meet the FDA CFR 21 part 11 regulations, and can be integrated with Tecan’s Freedom EVO liquid handling workstations or Freedom EVOlyzer ELISA analyzer.
 

 
Kinovate Life Sciences this week announced that it will officially launch CarriGene plates — a fast transfection plate product for the in vitro delivery of plasmid DNA to mammalian cells. CarriGene plates will be available in 6-, 12-, 24-well, and 10-cm dish formats for routine transfection and viral vector production, and a 96-well format for HTS applications. The plates are pre-coated with Kinovate's biodegradable cationic polymer transfection reagent.
 
According to the manufacturer, this patented technology is the first to offer a DNA transfection reagent pre-coated onto plates. Whereas conventional reagent transfection requires two overnight processes, CarriGene plates use a reverse-transfection protocol in which DNA solution is first added to the plate, followed by cell solution. Cell seeding and transfection occur simultaneously, reducing the entire process by one day.
 

 
Biophage Pharma launched its PDS Biosensor at this week’s Nanotoxicity 2007 trade show in Paris. The company said this product represents the first of many biosensors it has in development.
 
The PDS Biosensor allows for the rapid, simultaneous screening of a large number of toxic compounds, metals, and nanoparticles to determine their relative level of toxicity, Biophage said.
 
According to the company, it can also identify parameters that determine toxicity levels at various stages of development and manufacturing, which allows companies to explore different strategies to circumvent potential toxic effects or mitigate the risk to humans, animals, and the environment.
 

 
Invitrogen this week launched the Gibco AlgiMatrix 3D culture system, an animal origin-free bioscaffold that the company says more closely mimics the conditions of a cell in the human body.
 
AlgiMatrix, a macroporous alginate sponge structure, delivers more consistent results to support the growth of diverse cell types. In addition, it is available at room temperature.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.